NCT01019161View on ClinicalTrials.gov

An Open Label, Single Centre Mass Balance C14 Study in Patients With Acute Myeloid Leukaemia (AML)

PHASE1CompletedINTERVENTIONAL

Enrollment

5

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

June 30, 2010

Study Completion Date

June 30, 2010

Conditions

Acute Myeloid Leukaemia

Interventions

DRUG

AZD1152

100mg Lyophile, 5mL Diluent IV infusion

DRUG

C14 AZD1152

radiolabelled IV solution, 1.05 mg/ml presented as 15 ml fill in 20ml vial infusion

Trial Locations (1)

Unknown

Research Site, Manchester

Sponsors

Lead Sponsor

All Listed Sponsors

lead

AstraZeneca

INDUSTRY